share_log

Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11

Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11

派珀·桑德勒以增持评级开始对Allogene Therapeutics进行报道,宣布目标股价为11美元
Benzinga ·  05/31 05:53

Piper Sandler analyst Biren Amin initiates coverage on Allogene Therapeutics (NASDAQ:ALLO) with a Overweight rating and announces Price Target of $11.

派珀·桑德勒分析师比伦·阿明以增持评级启动了对Allogene Therapeutics(纳斯达克股票代码:ALLO)的报道,并宣布目标股价为11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发